Skip to main content
Premium Trial:

Request an Annual Quote

MicroGem Acquires Engineering Firm Jump Start to Support Coronavirus Test Production

NEW YORK — MicroGem said on Thursday that it has acquired engineering firm Jump Start Manufacturing in a move aimed at helping it scale up production of its Spitfire6830 PCR-based SARS-CoV-2 saliva test.

Terms of the acquisition were not disclosed.

MicroGem's Spitfire6830 uses a microfluidic cartridge and is designed to detect SARS-CoV-2 at the point of care with results available in 15 minutes. MicroGem recently received a $40.9 million contract from the National Institutes of Health to support development of the test, which the Charlottesville, Virginia-based company expects to submit to the US Food and Drug Administration for Emergency Use Authorization by the end of February, a company spokesperson said. 

MicroGem also said that it has established new manufacturing facilities in Utah and New Hampshire that, along with its operations in Charlottesville, will give it the capacity to produce 160,000 Spitfire6830 tests a day. The acquisition of Nashua, New Hampshire-based Jump Start is expected to speed production and deployment of the test, it said.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.